Literature DB >> 24960596

Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome.

Robert Phillips.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24960596     DOI： 10.1038/nrurol.2014.145

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Is there an antiandrogen withdrawal syndrome with enzalutamide?

Authors:  Alejo Rodriguez-Vida; Diletta Bianchini; Mieke Van Hemelrijck; Simon Hughes; Zafar Malik; Thomas Powles; Amit Bahl; Sarah Rudman; Heather Payne; Johann de Bono; Simon Chowdhury
Journal:  BJU Int       Date:  2014-10-24       Impact factor: 5.588
  1 in total
  2 in total

Review 1.  An update on enzalutamide in the treatment of prostate cancer.

Authors:  Axel S Merseburger; Gabriel P Haas; Christoph-A von Klot
Journal:  Ther Adv Urol       Date:  2015-02

2.  TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.

Authors:  Ken-ichi Takayama; Aya Misawa; Takashi Suzuki; Kiyoshi Takagi; Yoshihide Hayashizaki; Tetsuya Fujimura; Yukio Homma; Satoru Takahashi; Tomohiko Urano; Satoshi Inoue
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 14.919
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.